injected with mouse-brain mRNA: correlation with convulsive potency in 23.
vivo. Toxicol. Appl. Pharmacol. 145:246–254.
13. Loewe, S. 1953. The problem of synergism and antagonism of combined
drugs. Arzneim. Forsh. 3:285–290. 24.
14. Maesen, F. P. V., J. P. Teengs, C. Baur, and B. I. Davies. 1984. Quinolones
and raised plasma concentrations of theophylline. Lancet ii:530.
15. Miyama, T., H. Takanaga, H. Matsuo, K. Yamano, K. Yamamoto, T. Iga, M. 25.
Naito, T. Tsuruo, H. Ishizuka, Y. Kawahara, and Y. Sawada. P-glycoproteinmediated transport of itraconazole across the blood-brain barrier. Antimi- 26.
crob. Agents Chemother. 42:1738–1744.
16. Nakamura, R., T. Yamaguchi, Y. Sekine, and M. Hashimoto. 1983. Deter- 27.
mination of a new antibacterial agent (AT-2266) and its metabolites in
plasma and urine by high-performance liquid chromatography. J. Chromatogr. 278:321–328.
28.
17. Paton, J. H., and D. S. Reeves. 1991. Clinical features and management of
adverse effects of quinolone antibacterials. Drug Safety 6:8–27.
18. Polk, R. E., D. P. Healy, J. Sahai, L. Drwal, and E. Racht. 1989. Effect of
ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in
normal volunteers. Antimicrob. Agents Chemother. 33:1841–1844. 29.
19. Sano, M., K. Kawakatsu, I. Yamamoto, M. Takeyama, H. Yamashina, and
M. Goto. 1989. Inhibitory effect of enoxacin, ofloxacin and norfloxacin on
renal excretion of theophylline in humans. Eur. J. Clin. Pharmacol. 36:323–
324. 30.
20. Schwarts, M. T., and J. F. Calvert. 1990. Potential neurologic toxicity related
to ciprofloxacin. Ann. Pharmacother. 24:138–140. 31.
21. Staib, A. H., W. Stille, G. Dietlein, P. M. Shah, S. Mieke, and C. Beer. 1987.
Interaction between quinolones and caffeine. Drugs 34(Suppl. 1):170–174.
22. Stille, W., S. Harder, S. Mieke, C. Beer, P. M. Shah, K. Frech, and A. H. 32.
Staib. 1987. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J. Antimicrob. Chemother. 20:729–734.
